Enveric Biosciences Inc (ENVB)
0.92
-0.06
(-6.12%)
USD |
NASDAQ |
May 06, 16:00
0.9114
-0.01
(-0.93%)
After-Hours: 20:00
Enveric Biosciences Net Income (Quarterly): -3.436M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -3.436M |
| September 30, 2023 | -2.822M |
| June 30, 2023 | -6.363M |
| March 31, 2023 | -4.690M |
| December 31, 2022 | -8.690M |
| September 30, 2022 | -2.492M |
| June 30, 2022 | -2.798M |
| March 31, 2022 | -4.524M |
| December 31, 2021 | -42.11M |
| September 30, 2021 | -2.712M |
| June 30, 2021 | -0.9083M |
| March 31, 2021 | -3.251M |
| December 31, 2020 | -4.382M |
| September 30, 2020 | -0.5653M |
| June 30, 2020 | -0.8184M |
| March 31, 2020 | -1.784M |
| December 31, 2019 | -2.529M |
| September 30, 2019 | 0.0413M |
| June 30, 2019 | -1.257M |
| March 31, 2019 | -1.86M |
| December 31, 2018 | -19.76M |
| September 30, 2018 | 5.700M |
| June 30, 2018 | -1.260M |
| March 31, 2018 | -1.572M |
| December 31, 2017 | -1.006M |
| Date | Value |
|---|---|
| September 30, 2017 | -4.068M |
| June 30, 2017 | -3.279M |
| March 31, 2017 | -0.722M |
| December 31, 2016 | 1.301M |
| September 30, 2016 | -1.778M |
| June 30, 2016 | -1.209M |
| March 31, 2016 | -1.160M |
| September 30, 2015 | -0.2494M |
| June 30, 2015 | 0.111M |
| March 31, 2015 | -0.0026M |
| December 31, 2014 | -0.0107M |
| September 30, 2014 | -0.0032M |
| June 30, 2014 | -0.0119M |
| March 31, 2014 | -0.0079M |
| December 31, 2013 | 0.013M |
| September 30, 2013 | -0.0046M |
| June 30, 2013 | -0.0039M |
| March 31, 2013 | -0.0047M |
| December 31, 2012 | -0.0116M |
| September 30, 2012 | -0.0049M |
| June 30, 2012 | -0.0041M |
| March 31, 2012 | -0.004M |
| December 31, 2011 | -0.015M |
| September 30, 2011 | -0.0037M |
| June 30, 2011 | -0.0036M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-42.11M
Minimum
Dec 2021
0.0413M
Maximum
Sep 2019
-5.057M
Average
-2.798M
Median
Jun 2022
Net Income (Quarterly) Benchmarks
| Seelos Therapeutics Inc | -5.453M |
| Societal CDMO Inc (DELISTED) | -0.786M |
| Cardiff Oncology Inc | -10.01M |
| BioVie Inc | -8.401M |
| Adial Pharmaceuticals Inc | -1.920M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 4.233M |
| EPS Diluted (Quarterly) | -1.47 |
| Enterprise Value | 4.422M |
| Earnings Yield | -882.6% |
| Normalized Earnings Yield | -69820.34 |